| Identification | Back Directory | [Name]
Fidasimtamab | [CAS]
2377419-89-9 | [Synonyms]
BH2950)
Fidasimtamab
Fidasimtamab (Synonyms: IBI-315
Research Grade Fidasimtamab (DHC09614) |
| Hazard Information | Back Directory | [Uses]
Fidasimtamab (IBI-315; BH2950) is a recombinant human IgG1 bispecific antibody that targets, binds and inhibits both HER2 and PD-1 and their downstream signalling pathways, and links PD-1 expressing T cells to HER2 expressing tumour cells. Fidasimtamab has potential immunosuppressive and antitumor activity[1]. | [References]
[1] Shijie Jin, et al. Emerging new therapeutic antibody derivatives for cancer treatment. Signal Transduct Target Ther. 2022 Feb 7;7(1):39. DOI:10.1038/s41392-021-00868-x |
|
| Company Name: |
Biolab Reagents
|
| Tel: |
18108604356 |
| Website: |
www.biolabreagent.com/ |
| Company Name: |
Cell Sciences
|
| Tel: |
9785721070 |
| Website: |
www.cellsciences.com |
| Company Name: |
Biorbyt Ltd.
|
| Tel: |
+44 (0)1223 859 353 |
| Website: |
http://www.biorbyt.com |
|